Study demonstrates CV safety of Trajenta, including heart failure (Ref. 1)

esults from the CARMELINA® Study (CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin) published in the Journal of the American Medical Association (JAMA) provide important evidence of the safety of Trajenta (linagliptin) in patients with type 2 diabetes with high cardiovascular and/or renal risk.1